DPP-4 inhibitors: Difference between revisions
| Line 36: | Line 36: | ||
=== '''Adverse Effects''' === | === '''Adverse Effects''' === | ||
In controlled clinical studies of sitagliptin as monotherapy and combination therapy, the overall incidence of adverse reactions and the discontinuation of therapy in those taking sitagliptin was similar to that in those taking the placebo. The most commonly reported adverse reactions include '''nasopharyngitis''', '''upper respiratory tract infection''' and '''headache'''. | |||
Postmarketing surveillance found an association between those taking sitagliptin and development of '''acute pancreatitis''', though confounding variables include risk factors such as diabetes, hypercholesterolemia, hypertriglyceridemia and obesity. Approximately 3 months after sitigliptin initiation, there were also reports of '''serious allergic reactions''' including anaphylactoid reactions, angioedema and exfoliate dermatologic reactions such as Stevens-Johnson syndrome. | |||
Studies of other drugs in this class additionally report lymphopenia, cough, peripheral edema, transaminitis, and hypertension. | |||
Patients taking DPP-4 inhibitors have also been found to develop '''joint pain''', which often ceased within a month of discontinuation of the medication. | |||
=== '''References''' === | === '''References''' === | ||
US Food and Drug Administration. "FDA Drug Safety Communication: FDA warns that DPP-4 inhibitors for type 2 diabetes may cause severe joint pain." FDA, 6/23/2016. http://www.fda.gov/Drugs/DrugSafety/ucm459579.htm | US Food and Drug Administration. "FDA Drug Safety Communication: FDA warns that DPP-4 inhibitors for type 2 diabetes may cause severe joint pain." FDA, 6/23/2016. http://www.fda.gov/Drugs/DrugSafety/ucm459579.htm | ||
Revision as of 19:02, 30 December 2016
Introduction
Dipeptidyl Peptidase-4 Inhibitors (gliptans) are a class of oral hypoglycemics that block DPP-4. This leads to an increase in the activity of incretins, which inhibit glucagon release, which in turn increase insulin secretion and slow gastric emptying, ultimately decreasing blood glucose levels. These drugs are commonly used in the treatment of type 2 diabetes.
FDA Approved DPP-4 Inhibitors
| Brand Name | Active Ingredient(s) |
|---|---|
| Januvia | sitagliptin |
| Janumet | sitagliptin, metformin |
| Janumet XR | sitagliptin, metformin ER |
| Onglyza | saxagliptin |
| Kombiglyze XR | saxagliptin, metformin ER |
| Tradjenta | linagliptin |
| Glyxambi | linagliptin, empagliflozin |
| Jentadueto | linagiptin, metformin |
| Nesina | alogliptin |
| Kazano | alogliptin, metformin |
| Oseni | alogliptin, pioglitazone |
Mechanism of Action
DPP-4 inhibitors inhibit the enzyme DPP-4, which is expressed on the surface of most cell types. DPP-4 deactivates other bioactive peptides, including incretins like glucagon-like peptide-1 (GLP-1). GLP-1 is secreted in the small intestines in response to nutrients, stimulating glucose-dependent insulin release from the pancreatic islets. Additionally, it decreases gastric emptying and inhibits postprandial glucagon release.
Indications
Adverse Effects
In controlled clinical studies of sitagliptin as monotherapy and combination therapy, the overall incidence of adverse reactions and the discontinuation of therapy in those taking sitagliptin was similar to that in those taking the placebo. The most commonly reported adverse reactions include nasopharyngitis, upper respiratory tract infection and headache.
Postmarketing surveillance found an association between those taking sitagliptin and development of acute pancreatitis, though confounding variables include risk factors such as diabetes, hypercholesterolemia, hypertriglyceridemia and obesity. Approximately 3 months after sitigliptin initiation, there were also reports of serious allergic reactions including anaphylactoid reactions, angioedema and exfoliate dermatologic reactions such as Stevens-Johnson syndrome.
Studies of other drugs in this class additionally report lymphopenia, cough, peripheral edema, transaminitis, and hypertension.
Patients taking DPP-4 inhibitors have also been found to develop joint pain, which often ceased within a month of discontinuation of the medication.
References
US Food and Drug Administration. "FDA Drug Safety Communication: FDA warns that DPP-4 inhibitors for type 2 diabetes may cause severe joint pain." FDA, 6/23/2016. http://www.fda.gov/Drugs/DrugSafety/ucm459579.htm